REVEAL Study Completes Enrollment

The Immune Tolerance Network (ITN) officially completed enrollment this week for the REVEAL study with 59 participants.  Led by Dr. Brett King at Yale University, the REVEAL study is testing whether the experimental study medication, AMG 714, can bring back normal color to the skin (repigmentation) in vitiligo.  

The REVEAL study is being conducted at 7 clinical centers across the US (University of California Davis, University of California Irvine, Yale University, Tufts Medical Center, University of Massachusetts, Henry Ford Health System and Northwell Health). The REVEAL study should be completed by April 2025.  More information on the REVEAL can be found at https://clinicaltrials.gov/study/NCT04338581